Technology

Peptomyc technology and IP is founded on the knowledge accumulated by Dr. Soucek‘s lab on Omomyc, a dominant-negative Myc mutant that is the most efficacious and safe direct Myc inhibitor to date and that shows great therapeutic promise in a variety -if not all- cancer types. Omomyc was considered a proof of principle for many years, and its application was to be limited to gene therapy. However, Dr. Soucek’s lab has shown that the Omomyc peptide itself displays excellent cell penetrating properties and can efficiently enter cells and exert a strong anti-Myc activity that results in arrest/death of cancer cell lines. Peptomyc now aims to further develop the Omomyc peptide – and improved variants – into clinically viable therapeutics for the treatment of cancer patients.

Relevant publications:

  1. Soucek, L., Helmer-Citterich, M., Sacco, A., Jucker, R., Cesareni, G., and Nasi, S. (1998). Oncogene 17, 2463-2472.
  2. Soucek, L., Jucker, R., Panacchia, L., Ricordy, R., Tato, F., and Nasi, S. (2002). Cancer Research 62, 3507-3510.
  3. Annibali, D., Whitfield, J.R., Favuzzi, E., Jauset, T., Serrano, E., Cuartas, I., Redondo-Campos, S., Folch, G., Gonzalez-Junca, A., Sodir, N.M., et al. (2014). Nature Communications 5, 4632.
  4. Sodir, N.M., Swigart, L.B., Karnezis, A.N., Hanahan, D., Evan, G.I., and Soucek, L. (2011). Genes & Development 25, 907-916.
  5. Soucek, L., Nasi, S., and Evan, G.I. (2004). Cell Death and Differentiation 11, 1038-1045.
  6. Soucek, L., Whitfield, J., Martins, C.P., Finch, A.J., Murphy, D.J., Sodir, N.M., Karnezis, A.N., Swigart, L.B., Nasi, S., and Evan, G.I. (2008). Nature 455, 679-683.
  7. Soucek, L., Whitfield, J.R., Sodir, N.M., Masso-Valles, D., Serrano, E., Karnezis, A.N., Swigart, L.B., and Evan, G.I. (2013). Genes & Development 27, 504-513.
  8. Savino, M., Annibali, D., Carucci, N., Favuzzi, E., Cole, M.D., Evan, G.I., Soucek, L., and Nasi, S. (2011). PloS One 6, e22284.

Cells